ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO1078

Clinical Utility of Tenascin-C Levels in Patients with CKD

Session Information

Category: CKD (Non-Dialysis)

  • 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Lim, Zhen Yu Z., National University Hospital, Singapore, Singapore, Singapore
  • Mohamad, Hazirah, National University Hospital, Singapore, Singapore, Singapore
  • Chan, Gek Cher, National University Hospital, Singapore, Singapore, Singapore
  • Teo, Boon Wee, National University Hospital, Singapore, Singapore, Singapore

Tenascin-C (TNC), an extracellular matrix protein, is a novel biomarker associated with kidney fibrosis. Within the kidney, it activates fibroblasts and induces epithelial-mesenchymal transition. Increased levels of TNC have been seen in kidney biopsies of patients with chronic kidney disease (CKD). Current literature lacks studies evaluating TNC and associations with clinical parameters and clinical outcomes.


We retrieved prospectively collected 24-hour urinary and plasma samples from 126 CKD patients and 99 healthy participants. TNC levels were assayed using IBL Tenascin-C Large (FNIII-B) assay kit. TNC concentration was assessed for associations with serum creatinine, cystatin-C, eGFR albuminuria, and rate of eGFR decline. Other factors evaluated include age, gender and body mass index. Differences in TNC concentration between groups were compared using analysis of variance, chi-squared tests. Univariate analysis was performed to assess correlation between TNC and variables of interest. Multiple regression analysis was performed to identify predictors of eGFR decline/year. Significance was taken at P < 0.05.


CKD patients versus healthy participants: age (59 vs. 42), gender (44% female vs. 51%), non-smokers (78% vs. 81%), BMI (27.7 vs. 24.8), eGFR (45 vs. 100mL/min/1.73m2), serum creatinine (171 vs. 69 µmol/L). 24-hour urinary concentration of TNC is elevated in CKD patients (1.45 vs. 0.32ng/ml, p<0.001). It is associated with serum creatinine levels (p<0.001), serum cystatin-C levels (p<0.001), eGFR (p<0.001) and albuminuria (<0.001). Urinary TNC concentration is highest in patients with diabetes mellitus (DM, n=52), followed by non-DM (n=43) and healthy controls (n=92). (1.86, 0.95, 0.32ng/ml, p<0.001). In CKD patients, urinary TNC concentration is associated with rate of eGFR decline/year (p<0.001). Plasma TNC concentration was not associated with eGFR, albuminuria and GFR decline.


24-hour urinary tenascin C level offers novel clinical utility in management of patients with CKD. Early detection of high risk CKD patients will allow for earlier intervention and may serve to delay ESKD onset.


  • Other NIH Support